Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638399 | 0.87 | CNR2 (0.42) | HSD11B1GRM5CNR2TSHRPBK | |
| SCHEMBL3374565 | 0.86 | PBK (0.53) | GRM5CNR2TSHRPBKCNR1 | |
| SCHEMBL11028516 | 0.81 | GRM5 (0.58) | GRM5BACE1 | |
| SCHEMBL11030537 | 0.81 | GRM5 (0.58) | GRM5BACE1 | |
| SCHEMBL11027977 | 0.81 | GRM5 (0.58) | GRM5BACE1 | |
| SCHEMBL2638164 | 0.81 | RAB9A (0.56) | HSD11B1GRM5TSHRRAB9AEPHX2 | |
| SCHEMBL1578858 | 0.78 | GRM5 (0.53) | GRM5CNR2CNR1NPC1 | |
| SCHEMBL2638469 | 0.78 | CNR2 (0.42) | HSD11B1GRM5CNR2TSHRPBK | |
| SCHEMBL2638285 | 0.78 | PABPC1 (0.44) | HSD11B1GRM5PBKNPC1RAB9A | |
| SCHEMBL3377026 | 0.77 | TSHR (0.71) | HSD11B1GRM5TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | HSD11B1 442/4885GRM5 3873/4885CNR2 1628/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | HSD11B1 386/4885GRM5 3895/4885CNR2 1603/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | HSD11B1 318/4885GRM5 4054/4885CNR2 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.